Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
Taking everything into account, 56S1 scores 4 out of 10 in our fundamental rating. 56S1 was compared to 22 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 is valued quite expensive, but it does show an excellent growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.66 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.25 | ||
| Fwd PE | 41.14 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.41 | ||
| EV/EBITDA | 29.43 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
FRA:56S1 (1/8/2026, 7:00:00 PM)
220.9
-1.9 (-0.85%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.25 | ||
| Fwd PE | 41.14 | ||
| P/S | 7.3 | ||
| P/FCF | 57.41 | ||
| P/OCF | 29.43 | ||
| P/B | 5.33 | ||
| P/tB | N/A | ||
| EV/EBITDA | 29.43 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.66 |
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE.
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 51.25 and the Price/Book (PB) ratio is 5.33.
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.39% in the next year.